共 102 条
[11]
Aschele C(2010)Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer [abstract no. 3511] J Clin Oncol. 28 3511-1044
[12]
Cionini L(2012)Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial [abstract no. 3586] J Clin Oncol. 30 3586-971
[13]
Lonardi S(2011)Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer Jpn J Clin Oncol. 41 1041-29
[14]
Rödel C(2013)Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II Trial Jpn J Clin Oncol. 43 964-895
[15]
Liersch T(2012)Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer Int J Clin Oncol. 17 1-200
[16]
Becker H(2006)Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0 J Nucl Med. 47 885-23
[17]
Fernández-Martos C(2010)FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging. 37 181-732
[18]
Pericay C(1997)Pathological features of rectal cancer after preoperative radiochemotherapy Int J Colorectal Dis. 12 19-2852
[19]
Aparicio J(2013)Neoadjuvant chemotherapy evaluation by MRI volumetry in rectal cancer followed by chemoradiation and total mesorectal excision: initial experience J Magn Reson Imaging. 38 726-171
[20]
Maréchal R(2012)Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer Ann Surg Oncol. 19 2842-418